文献速递肝病消化道肿瘤与早癌

噻唑烷二酮类与GLP-1受体激动剂及非酒精性脂肪性肝病风险:队列研究

Thiazolidinediones and Glucagon-Like Peptide-1 Receptor Agonists and the Risk of Nonalcoholic Fatty Liver Disease: A Cohort Study.
PubMed 文献 · Hepatology · 2021-08-22

基于英国临床实践研究数据链(2007-2018)的队列研究,纳入207,367例接受降糖药处方的成人,比较噻唑烷二酮类(TZDs)与磺脲类(SUs)、GLP-1受体激动剂与胰岛素对NAFLD新诊断风险的影响。TZDs使用者NAFLD风险低于SUs使用者(aHR 0.32,95%CI 0.20-0.51),GLP-1受体激动剂与胰岛素使用者间无差异(aHR 1.22,95%CI 0.91-1.63)。

要点

  • TZDs与较低NAFLD风险相关,支持在特定风险患者中使用。
  • GLP-1受体激动剂与胰岛素相比未显示NAFLD风险获益。
  • 部分亚组事件数少,结论外推需谨慎。

核心结论

  • TZDs使用者NAFLD风险低于SUs使用者,支持在特定NAFLD风险患者中使用TZDs。
  • GLP-1受体激动剂与胰岛素相比未观察到NAFLD风险差异,不支持其有益作用的既往发现。

研究设计与样本

  • 基于临床实践研究数据链(2007-2018)的 population-based 队列研究。
  • 纳入207,367例年龄≥18岁、首次处方口服降糖药或GLP-1受体激动剂的成人,首次处方定义随访起点。

主要发现

  • TZDs与SUs相比,NAFLD新诊断风险较低(aHR 0.32;95%CI 0.20-0.51)。
  • GLP-1受体激动剂与胰岛素相比,NAFLD风险无差异(aHR 1.22;95%CI 0.91-1.63)。
  • 按每1,000人年计算了所有暴露的HCC发生率(具体数值原文未提供)。

关键数值与推荐

  • 主要结局为新诊断NAFLD,采用Cox比例风险回归估计HR和95%CI。

临床怎么用

  • 对于有NAFLD风险的特定2型糖尿病患者,可考虑优先选用TZDs。
  • 不应仅基于NAFLD预防目的将GLP-1受体激动剂替代胰岛素。

局限性

  • 部分亚组事件数少,可能影响当前发现的普遍性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Thiazolidinediones (TZDs) and glucagon-like peptide-1 (GLP-1) receptor agonists are potential pharmacological treatment options for patients at risk of NAFLD. Therefore, we examined the association between the risk of NAFLD and the use of TZDs and GLP-1 receptor agonists compared with the use of sulfonylureas (SUs) and insulins. Additionally, we calculated the incidence of HCC in users of TZDs and GLP-1 receptor agonists. APPROACH AND RESULTS: We conducted a population-based cohort study using primary care data from the Clinical Practice Research Datalink database (2007-2018). All patients aged ≥18 with a prescription of an oral glucose-lowering agent or GLP-1 receptor agonist were included. The first prescription defined the start of follow-up. The primary outcome was a new diagnosis of NAFLD. Cox proportional hazards regression was used to estimate HRs and 95% CIs of the primary outcome. Incidence rates of HCC were determined per 1,000 person-years for all exposures. The study identified 207,367 adults with a prescription for a glucose-lowering agent. The risk of NAFLD was lower in patients prescribed a TZD than in those prescribed an SU (adjusted HR [aHR], 0.32; 95% CI, 0.20-0.51). No difference in risk of NAFLD was observed comparing GLP-1 receptor agonist use with insulin use (aHR, 1.22; 95% CI, 0.91-1.63). CONCLUSIONS: Results of our study endorse the use of TZDs for selected patients at risk of NAFLD but do not support previous findings regarding the beneficial effect of GLP-1 receptor agonists. The low number of events in several subgroups may affect the generalizability of the current findings.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. van Dalem J, Driessen JHM, Burden AM, et al. Thiazolidinediones and Glucagon-Like Peptide-1 Receptor Agonists and the Risk of Nonalcoholic Fatty Liver Disease: A Cohort Study. Hepatology. 2021. PMID: 34129693. doi:10.1002/hep.32012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。